The human IL-6 promoter contains multiple regulatory elements such as those binding transcription factors belonging to the NF-nB ( À 75/ À 63), C/EBP ( À 158/ À 145 and À 87/ À 76) and AP-1 ( À 283/ À 277) families. Herein, we report that ectopic expression of c-Jun, C/EBPy, and the p65 subunit of NF-nB synergistically activates an IL-6 promoter construct containing only a TATA box and a nB binding site. These results suggest that interactions among NF-nB, C/EBP, and AP-1, which are all activated by the most powerful physiological inducers of the IL-6 gene, namely TNF-a and IL-1, may be crucial for maximal activation of the IL-6 promoter in response to the two cytokines. Furthermore, we show that a mutated form of c-Jun lacking the transactivation domain (TAM-67) was a much stronger activator of the IL-6 promoter than c-Jun. In combination with p65 and/or C/EBPy, TAM-67 also synergistically activated the IL-6 promoter, while it inhibited TNF-a induced AP-1 activity directing an AP-1-responsive reporter plasmid. Lastly, electrophoretic mobility shift assay (EMSA) results strongly suggest the formation of complexes between p65, C/EBPy, and/or c-Jun or TAM-67 on the nB site, supporting the idea that the functional synergism is determined by a physical interaction. These data provide new insight into the molecular mechanisms regulating the formation of the transcription complex responsible for IL-6 promoter activation. D
Introduction
Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a major role in immunological responses, inflammation, bone metabolism, neoplasia, and aging [1] [2] [3] . A number of transcription factors contribute to the complex regulation of the IL-6 gene and their interactions may vary depending on the cell type as well as the extracellular stimuli. Functional cisregulatory elements described to date in the human IL-6 promoter include IRF-1 ( À 267 to À 254) [4] , AP-1 ( À 283 to À 277) [5] , C/EBP ( À 158 to À 145 and À 87 to À 76) [6, 7] , Sp1 ( À 123 to À 119 and À 108 to À 104) [8, 9] and NF-nB ( À 75 to À 63) [10] binding sites.
NF-nB belongs to the Rel family of transcription factors that form homo-or heterodimers through the Rel homology domain [7, 11] . In most cells, NF-nB is present in the cytoplasm bound to a member of the InB family of inhibitors [12, 13] . Upon activation of the cells by cytokines, such as TNF-a and IL-1, viruses, bacteria, or mitogens, InB is phosphorylated and then rapidly degraded allowing the translocation of NF-nB to the nucleus where it binds to specific DNA binding sites.
The C/EBP family of transcription factors belongs to a class of DNA binding proteins called bZIP proteins, which are characterized by a basic leucine-zipper structure that is responsible for their homo-and hetero-dimerization [7] . Two members of the family, C/EBPh and C/EBPy, have been shown to play a role in the induction of the IL-6 gene [14, 15] . C/EBPh is expressed at low levels and is strongly induced by TNF-a, IL-1, LPS or IL-6 in normal tissues, whereas it is expressed constitutively in many cell lines [14] . C/EBPy, which is a stronger transactivator than C/ EBPh of the IL-6 gene transcription, is normally expressed at low levels and is markedly induced by TNF-a, IL-1, LPS, or IL-6 in normal tissues and cell lines [15] . Both C/ EBPh [7] and C/EBPy [16] have been shown to increase their transcriptional potential following phosphorylation.
Transfection studies with an IL-6 promoter-reporter construct have shown that overexpression of the p65 subunit of NF-nB, together with C/EBP factors, is able to activate the reporter gene. This suggests that the two factors alone are sufficient to sustain the activation of the IL-6 gene [17, 18] .
The AP-1 transcription factors are homodimers and heterodimers composed of basic region-leucine zipper proteins that belong to the Jun and Fos subfamilies [19] . Fos proteins do not form stable dimers, but can bind DNA by forming heterodimers with Jun proteins. The DNA binding affinities and transactivation capacities of the Jun proteins vary considerably, with c-Jun exhibiting the highest activation potential [20] . AP-1 activity is induced by several stimuli, such as serum, growth factors, oncoproteins, TNFa, and IL-1 [19, 21] .
Several lines of evidence suggest that members of the NF-nB, C/EBP, and AP-1 transcription factor families may work in concert to regulate the IL-6 promoter in a cell-typeor inducer-specific fashion [17, 18, 22, 23] . Indeed, a physical and functional interplay among all three classes of proteins has been widely demonstrated [7, 24, 25] . However, prior studies have not clarified the contribution of each transcription factor and its respective recognition site to IL-6 promoter activation.
In the present study, we have analyzed the role of various cis-acting regulatory elements of the IL-6 promoter and of the p65 subunit of NF-nB, c-Jun, and C/EBPy in the transcriptional regulation of the IL-6 gene. We show that an IL-6 promoter/reporter construct containing only the TATA box and the NF-nB binding site was sufficient to obtain the maximal activation of the reporter gene by ectopically expressed p65, c-Jun, and C/EBPy. In addition, we show by electrophoretic mobility shift assay (EMSA) that p65 forms higher affinity and faster migrating complexes with the nB site, in the presence of C/EBPy and/or cJun or TAM-67. These results indicate that the complex responsible for optimal transcription of the IL-6 gene requires interaction between NF-nB, C/EBP, and c-Jun on the nB site. Interestingly, TAM-67, a mutant form of c-Jun lacking the transcriptional transactivation domain, activates the IL-6 promoter with an efficiency much stronger than that of c-Jun, suggesting that the c-Jun transactivation domain may interfere with the formation of an optimal transcriptional complex, in contrast to other transcriptional systems studied to date [24 -27] .
Materials and methods

Cell lines and treatments
HeLa cells were grown in DMEM supplemented with 20 mM glutamine, 50 Ag/ml gentamycin and 10% FBS (BioWhittaker, Italy). TNF-a (specific activity 2 Â 10 7 U/mg) was obtained from Sigma.
Plasmids
The plasmids pIL6(-592) and pIL6(-225) were obtained by inserting the MscI/XhoI and NheI/XhoI fragments of the human IL-6 gene promoter into pGL3 basic (Promega). The pIL6( À 100), pIL6( À 80), and pIL6( À 60) plasmids were kindly provided by D.M. Klinman (Section of Retroviral Immunology Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, USA). The pIL6( À 592)/mut-nB was obtained by PCR amplification using an oligonucleotide mutated in the nB site which does not bind NF-nB (5V-AATGTAAT ATTTTCCCATG-3V). The eukaryotic expression vectors carrying the coding regions of p65 and InBa under control of the CMV promoter were gifts of A. Israel (Institute Pasteur, Paris, France) and P.A. Bauerle (University of Freiburg, Germany), respectively. The expression vector for C/EBPy which contains the C/EBPy coding sequence downstream of the CMV promoter/enhancer sequence was kindly provided by S. Akira and T. Kishimoto (Department of Medicine III, Osaka University Medical School, Suita, Japan). Expression vectors for c-Jun and TAM67 which contain coding sequences for the proteins downstream to the CMV promoter sequence were kindly provided by S.M. Cole (Northwestern University Medical School, Chicago, USA) and M.J. Birrer (National Cancer Institute, Rockville, Maryland, USA), respectively. The pSVhgal plasmid was obtained from Promega.
Transient transfection and reporter gene assay
Exponentially growing HeLa cells were seeded at a density of 2.5 Â 10 5 cells per well in six-well plates. Twenty-four hours later, transfections were carried out with Fugene6 Transfection Reagent (Roche) at a transfection reagent/DNA ratio of 3:2. The total amounts of expression vectors were kept constant by adding an empty pCMV vector. In each transfection, 0.2 Ag of the plasmid pSVhgal was added. Cells were incubated for 24 h, luciferase activity was then determined using the Luciferase Assay System (Promega) according to the manufacturer's instructions and normalized with respect to the h-galactosidase activity. Transfection efficiency was consistently about 15%.
In vitro translation and EMSA
In vitro transcription and translation of p65, C/EBPy, cJun, and TAM-67 was carried out using the TNT coupled Reticulocyte Lysate Systems (Promega). The translated products obtained in the presence of 35 S-methionine were identified by molecular weight in SDS PAGE. The efficiency of the translation was similar for all vectors. Binding reactions were carried out in a final volume of 20 Al using 2 Al of in vitro translated product in 20 mM Tris pH 7.5, 100 mM KCl, 0.1 mM DTT, 1 mM EDTA, 0.1% NP-40, 5% glycerol containing 1-Ag poly(dI -dC)Ápoly(dI-dC) (Amersham, Milan, Italy) and 1-Ag BSA. Radiolabelled probe (0.02 pmol; sp. act. f 3 Â 10 6 cpm/pmol) was added last to each reaction mixture and samples were incubated at room temperature for 30 min. In competition assays, a 200-fold molar excess of cold double-stranded oligonucleotides was added to the reaction mixture. Samples were then loaded on a 5% (30:1.2) native polyacrylamide gel in 0.5 Â TBE and run at 150 V, dried, and exposed to Kodak films.
The sequence of the IL6-nB oligonucleotide is as follows (only the sequence of the ''sense'' strand is indicated): 5V-AATGTGGGATTTTCCCATG-3V.
Results
Induction of the IL-6 promoter by p65, C/EBPd or c-Jun
In order to clarify the concerted mechanism of NF-nB, AP-1 and C/EBP interactions on the IL-6 promoter, we focused our studies on p65, c-Jun, and C/EBPy, which have been shown to be the most efficient activators of IL-6 transcription with respect to other members of the respective families [15, 18, 28 , and our unpublished results]. The ability of p65, c-Jun, or C/EBPy to activate a 592-bp IL-6 promoter luciferase reporter plasmid and various deletion mutant constructs was assessed. The activation of the À 225 IL-6 promoter construct (Fig. 1) by p65 was similar to that of the À 592 construct, while further deletions of the promoter up to À 80 resulted in a significant decrease of luciferase activity, similar to that of the À 60 construct. These results indicate that p65 is unable to activate an IL-6 promoter construct containing only the TATA box and the nB site. C/EBPy activation was optimal on the À 225 construct, suggesting that the region between À 592 and À 225 contains a negative regulatory element. Successive deletions of the IL-6 promoter up to nucleotides À 100 and À 80 resulted in a progressive reduction in luciferase activity, indicating that the upstream and the downstream C/EBP sites are both relevant for the C/EBPy-mediated activity of the IL-6 promoter. Overexpression of c-Jun slightly activated the À 100 construct (Fig. 1) , which does not contain the AP-1 site, suggesting that this site is not necessary for the activation of the IL-6 promoter by c-Jun.
Synergistic activation of the IL-6 promoter by p65, c-Jun, and C/EBPd
It has been widely demonstrated that p65, c-Jun, and C/ EBP physically interact with each other via the Rel homology and the leucine zipper domains [7, 24, 25] . Then, in order to examine the functional interactions between p65, c-Jun, and C/EBPy within the IL-6 promoter, we performed transfection experiments in HeLa cells with combined ectopic expression of p65, c-Jun, and C/EBPy. All deletion mutant constructs of the IL-6 promoter were synergistically activated by association with p65/c-Jun, p65/C/EBPy, and p65/c-Jun/C/EBPy, while only the À 100 and À 80 constructs were synergistically activated by c-Jun/C/EBPy (cf. Figs. 1 and 2) . The contribution of cJun to transcriptional activity was independent of the presence of its own binding site ( À 283/ À 277), as demonstrated in Fig. 1 . C/EBPy showed the maximal transactivation potential on the À 100 construct together with p65 and on the À 80 construct together with c-Jun. This indicates that the À 87/ À 76 C/EBP site, as well as the nB site, is important for the interaction of p65 with C/EBPy in the absence of c-Jun. On the other hand, the À 87/ À 76 C/ EBP site is not required for the synergism of c-Jun with C/ EBPy, which depends exclusively on the nB site. Indeed, overexpression of InBa together with c-Jun and C/EBPy significantly reduced the activity of the À 80 construct (Fig. 2) , suggesting that c-Jun and C/EBPy interact on the nB site via the constitutively expressed NF-nB. In line with this result, the maximal activation of each construct was obtained with the association of p65, C/EBPy, and cJun and reached the highest level on the À 80 construct. Taken together, these results demonstrate that both c-Jun and C/EBPy are capable of activating the IL-6 promoter in the absence of their respective binding sites, but require the presence of the nB site and constitutive or overexpressed p65. According to this result, p65 alone did not induce luciferase activity from a À 592 construct containing a point mutation in the nB site nor did it synergize with c-Jun or C/EBPy (Fig. 3) . This indicates that p65 is unable to functionally interact with c-Jun or C/EBPy on their respective recognition sites.
Activation of the IL-6 promoter by a c-Jun lacking the transactivation domain
To further characterize the mechanism of IL-6 transcription activation by c-Jun, we performed transient transfection assays with a vector expressing a dominant negative mutant of c-Jun lacking the transactivation domain (TAM-67) [25, 26] . Surprisingly, cotransfection of TAM-67 alone with the various deleted IL-6 promoter constructs resulted in an activation of luciferase activity stronger than that obtained with c-Jun and similar to that observed with p65 overexpression (Fig. 4) . Accordingly, cotransfection of TAM-67 together with p65 and/or C/ EBPy gave rise to a much stronger activation than that obtained with p65/c-Jun, c-Jun/C/EBPy, or p65/c-Jun/C/ EBPy. These results suggest that the c-Jun transactivation domain may interfere with the formation of the optimal transcriptional complex on the IL-6 promoter. A control experiment demonstrated that TAM-67 was able to act in a dominant negative fashion by inhibiting c-Jun activity on TRE-CAT, an AP-1 responsive reporter plasmid (data not shown). Fig. 5 shows that TAM-67 activated the À 100 IL-6 promoter construct in synergy with p65 in a dose-dependent manner, while c-Jun did not provide greater activity at higher concentrations. Thus, TAM-67 specifically transactivates the IL-6 promoter, while it behaves as a dominant negative factor on an AP-1 responsive construct.
EMSA with in vitro translated p65, C/EBPd, c-Jun and TAM-67
To assay directly whether C/EBPy, c-Jun, and/or TAM-67 were physically associated with p65, EMSAs were performed using a 32 P-labelled oligonucleotide corresponding to the NF-nB binding site on the 5V-regulatory region of the human IL-6 gene and in vitro translated p65, C/EBPy, c-Jun, and TAM-67. As shown in Fig. 6 , a specific protein -DNA complex was observed with the p65 protein, as demonstrated by competition with an excess of the unlabelled oligonucleotide (lanes 1 and 2) . C/EBPy, c-Jun, and TAM-67 did not form any specific complex when incubated with the probe (lanes 3, 5 and 7) . However, in the presence of p65, each factor determined the appear- ance of a complex with slightly higher mobility and stronger intensity (lanes 4, 6 and 8) compared to the complex obtained with p65 alone (lane 1). Incubation of p65 with C/EBPy and c-Jun or TAM-67 further increased the mobility and the intensity of the complex (lanes 9 and 10). These results strongly suggest that C/EBPy and/or cJun or TAM-67 interact with p65 forming complexes with altered subunits composition and structural conformation, which would be responsible for differential migration and affinity of the complex. It has already been demonstrated, indeed, that p65 binds to its specific site as a homodimer, while its interaction with C/EBPy or c-Jun is likely to be heterodimeric [24] . Moreover, it is known that both NF-nB and Jun/Fos induce DNA bending, which increases the electrophoretic complex mobility [24] . Remarkably, TAM-67 determined the formation of a complex with p65 and/or C/EBPy having higher intensity compared to c-Jun. This observation supports our transfection data showing a stronger functional synergism of TAM-67 with p65 and C/EBPy compared to c-Jun.
Discussion
This study provides evidence for a strong synergism among members of the NF-nB, C/EBP, and AP-1 families of transcription factors, which occurs on the interleukin-6 promoter and requires only the NF-nB binding site. In addition, our data demonstrate that a mutated form of cJun lacking 120 amino acids of the N-terminal transactivation domain, namely TAM-67, is a strong activator of the IL-6 promoter. Indeed, transient transfection of HeLa cells showed that either alone or in association with p65 and/or C/EBPy, TAM-67 was capable of activating all the IL-6 promoter-reporter constructs tested, even in the absence of its own binding site, provided that the nB element was present. The overexpression of cJun also determined a similar but weaker pattern of IL-6 promoter activation, suggesting that the c-Jun transactivation domain may interfere with the formation of an optimal transcriptional complex, as opposed to other transcriptional systems [24 -27] . Consistent with our data, the TNF-a promoter was also activated by TAM-67 [29] . However, in contrast to our results, TAM-67 required the presence of an AP-1 binding site in order to activate the TNF-a promoter. The observation that c-Jun is a superior activator of the IL-6 and the TNF-a promoters when the transactivation domain is not present suggests a novel role for this transcription factor. Indeed, one may speculate that on these promoters c-Jun may behave as an adapter protein that stabilizes the multimeric transcription complex, increasing its activity. In other transcriptional systems [24 -27] , c-Jun would behave as an active member of the complex and synergism with other transcription factors would result from the combined usage of all transactivation domains.
AP-1 represents a key family of transcription factors transducing multiple mitogenic signals. Thus, dominant negative mutants of these proteins, such as TAM-67, have been designed as possible inhibitors of cancer cell growth [25, 30] . It has been recently demonstrated that TAM-67 inhibits the proliferation of some breast cancer cell lines (MCF-7), while it is ineffective on others (MDA-MB-231) [31] . Our data on the activation of the IL-6 promoter by TAM-67 together with observations on the TNF-a promoter [29] suggest that the differential growth inhibitory effect obtained in various cell lines may be ascribed to the ability of TAM-67 to differentially regulate target genes such as IL-6, TNF-a, or other not yet identified TAM-67 inducible genes which may be responsible for cellular growth.
The IL-6 promoter comprises several control regions that can be triggered by multiple pathways [1] . Physiological inducers of IL-6 gene expression, such as IL-1 [18] and TNF-a [18, 28] , require the presence of an intact nB site for IL-6 promoter activation. Furthermore, it has been suggested that NF-nB alone is both responsible and sufficient for responsiveness to TNFa [28] . Both IL-1 and TNF-a are powerful activators not only of NF-nB [7] , but also of C/EBP [7, 15, 16] and AP-1 [19] . Our data demonstrate that the p65 subunit of NF-nB cotransfected with the À 80 IL-6 promoter-reporter gene construct containing only the TATA box and the nB site is unable to induce luciferase activity by itself, while it strongly synergizes with C/EBPy and/or c-Jun or TAM-67. Hence, these results suggest that NF-nB alone is not sufficient for the responsiveness of the IL-6 promoter to IL-1 or TNF-a. Indeed, the contemporary activation of AP-1 and/or C/EBP by IL-1 or TNF-a may be necessary for the formation of an active transcription complex requiring interaction on the nB site between NF-nB and AP-1 and/or C/EBP. Transient transfection assays performed with the nB point mutated IL-6 promoter construct demonstrate that p65 is unable to functionally interact with either c-Jun or C/EBPy on their respective recognition sites as described for other systems [24, 32] . This finding suggests that the functional synergism between p65 and c-Jun or C/EBPy may occur only on the nB site (located at positions À 75/ À 63) of the IL-6 promoter, most likely due to its proximity to the TATA box, which would allow optimal association with the basal transcription complex. Moreover, our EMSA data showing the formation of higher affinity and migrating complexes between p65, C/EBPy and/or c-Jun or TAM-67 on the nB site strongly support the idea that the functional synergism is determined by a physical interaction.
In conclusion, our results provide evidence that the most favorable complex responsible for the transcription of the IL-6 gene requires the interaction between p65 and C/EBPy, and c-Jun occurring on the nB site. Moreover, c-Jun is capable of interacting with the complex in a manner that does not require the transactivation domain, suggesting it has a role as an adapter protein in the context of the IL-6 promoter activation.
